Vaxart (VXRT) 10-Q 12 Nov 19 2019 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 08, 2019
Document Information [Line Items]
Entity Registrant Name	Vaxart, Inc.
Entity Central Index Key	0000072444
Trading Symbol	vxrt
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		47,722,895
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(b) Security	Common Stock, $0.10 par value

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 19,558	$ 11,506
Accounts receivable	559	1,796
Prepaid expenses and other current assets	1,137	1,343
Total current assets	21,254	14,645
Property and equipment, net	1,469	1,066
Right-of-use assets, net	2,301
Intangible assets, net	17,526	19,413
Other long-term assets	145	103
Total assets	42,695	35,227
Current liabilities:
Accounts payable	1,049	962
Current portion of secured promissory note payable to Oxford Finance	2,454	1,667
Current portion of operating lease liability	820
Liability related to sale of future royalties, current portion	3,228	3,328
Other accrued liabilities	1,603	1,518
Total current liabilities	9,154	7,475
Operating lease liability, net of current portion	1,694
Long-term portion	12,926	14,413
Secured promissory note payable to Oxford Finance, net of current portion		1,944
Other long-term liabilities	18	157
Total liabilities	23,792	23,989
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred Stock: $0.10 par value; 5,000,000 shares authorized; none issued and outstanding as of September 30, 2019 or December 31, 2018
Common Stock: $0.10 par value; 100,000,000 shares authorized; 46,223,594 and 7,141,189 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively	4,622	714
Additional paid-in capital	124,533	108,513
Accumulated deficit	(110,252)	(97,989)
Total stockholders’ equity	18,903	11,238
Total liabilities and stockholders’ equity	$ 42,695	$ 35,227

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0.10	$ 0.10
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	46,223,594	7,141,189
Common stock, shares outstanding (in shares)	46,223,594	7,141,189

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue:
Revenue from Contract with Customer, Including Assessed Tax	$ 454,000	$ 281,000	$ 5,946,000	$ 2,392,000
Operating expenses:
Research and development	3,713,000	4,381,000	11,249,000	12,801,000
General and administrative	1,455,000	1,674,000	4,856,000	5,455,000
Impairment of intangible assets				1,600,000
Impairment of property and equipment		106,000		106,000
Total operating expenses	5,168,000	6,161,000	16,105,000	19,962,000
Operating loss	(4,714,000)	(5,880,000)	(10,159,000)	(17,570,000)
Other income and (expenses):
Bargain purchase gain				6,660,000
Interest income	58,000	11,000	97,000	52,000
Interest expense	(84,000)	(129,000)	(288,000)	(702,000)
Non-cash interest expense related to sale of future royalties	(500,000)	(532,000)	(1,560,000)	(1,298,000)
Loss on revaluation of financial instruments				(3,000)
Foreign exchange loss, net	11,000	(18,000)	(32,000)	(215,000)
Total other income and (expenses)	(515,000)	(668,000)	(1,783,000)	4,494,000
Net loss before income taxes	(5,229,000)	(6,548,000)	(11,942,000)	(13,076,000)
Provision for income taxes	31,000		294,000	29,000
Net loss	(5,260,000)	(6,548,000)	(12,236,000)	(13,105,000)
Series B and C preferred dividend				(339,000)
Net comprehensive loss attributable to common stockholders	$ (5,260,000)	$ (6,548,000)	$ (12,236,000)	$ (13,444,000)
Net loss per share - basic and diluted (in dollars per share)	$ (0.32)	$ (0.92)	$ (0.96)	$ (2.23)
Shares used to compute net loss per share - basic and diluted (in shares)	16,249,032	7,141,189	12,748,665	6,038,001
Customer Service Contracts [Member]
Revenue:
Revenue from Contract with Customer, Including Assessed Tax	$ 94,000		$ 94,000
Government Contract [Member]
Revenue:
Revenue from Contract with Customer, Including Assessed Tax		194,000		1,324,000
Royalty [Member]
Revenue:
Revenue from Contract with Customer, Including Assessed Tax	8,000	87,000	3,736,000	1,050,000
Non Cash Royalty Revenue [Member]
Revenue:
Revenue from Contract with Customer, Including Assessed Tax	$ 352,000		$ 2,116,000	$ 18,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]The September 2019 Offering [Member]Underwriters' Designees [Member]	Common Stock [Member]The September 2019 Offering [Member]	Common Stock [Member]The April 2019 Offering [Member]Underwriters' Designees [Member]	Common Stock [Member]The April 2019 Offering [Member]	Common Stock [Member]Placement Agents' Designees [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]The September 2019 Offering [Member]Underwriters' Designees [Member]	Additional Paid-in Capital [Member]The September 2019 Offering [Member]	Additional Paid-in Capital [Member]The April 2019 Offering [Member]Underwriters' Designees [Member]	Additional Paid-in Capital [Member]The April 2019 Offering [Member]	Additional Paid-in Capital [Member]Placement Agents' Designees [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]The September 2019 Offering [Member]Underwriters' Designees [Member]	Retained Earnings [Member]The September 2019 Offering [Member]	Retained Earnings [Member]The April 2019 Offering [Member]Underwriters' Designees [Member]	Retained Earnings [Member]The April 2019 Offering [Member]	Retained Earnings [Member]Placement Agents' Designees [Member]	Retained Earnings [Member]	The September 2019 Offering [Member]Underwriters' Designees [Member]	The September 2019 Offering [Member]	The April 2019 Offering [Member]Underwriters' Designees [Member]	The April 2019 Offering [Member]	Placement Agents' Designees [Member]	Total
Balances (in shares) at Dec. 31, 2017	1,221,064						138,492
Balances at Dec. 31, 2017	$ 1												$ 41,259						$ (79,982)						$ (38,722)
Issuance of common stock warrants													70												70
Stock-based compensation													387												387
Net loss																			(13,105)						(13,105)
Issuance of common stock upon conversion of convertible promissory notes, related parties (in shares)							1,571,702
Issuance of common stock upon conversion of convertible promissory notes, related parties							$ 157						35,420												35,577
Issuance of common stock upon conversion of convertible preferred stock (in shares)	(1,221,064)						1,918,543
Issuance of common stock upon conversion of convertible preferred stock	$ (1)						$ 192						(191)
Reclassification of warrant to equity													70												70
Issuance of common stock upon reverse merger (in shares)							3,510,439
Issuance of common stock upon reverse merger							$ 365						31,403												31,768
Issuance of common stock upon exercise of stock options (in shares)							2,013
Issuance of common stock upon exercise of stock options													13												13
Balances (in shares) at Sep. 30, 2018							7,141,189
Balances at Sep. 30, 2018							$ 714						108,361						(93,087)						15,988
Balances (in shares) at Jun. 30, 2018							7,141,189
Balances at Jun. 30, 2018							$ 714						108,178						(86,539)						22,353
Stock-based compensation													183												183
Net loss																			(6,548)						(6,548)
Balances (in shares) at Sep. 30, 2018							7,141,189
Balances at Sep. 30, 2018							$ 714						108,361						(93,087)						15,988
Balances (in shares) at Dec. 31, 2018							7,141,189
Balances at Dec. 31, 2018							$ 714						108,513						(97,989)						11,238
Issuance of common stock and warrants, net of offering costs (in shares)			26,124,828		925,455
Issuance of common stock and warrants, net of offering costs			$ 2,612		$ 93				$ 4,632		$ 7,648										$ 7,244		$ 7,741
Issuance of common stock warrants								$ 497		$ 333		$ 100								$ 497		$ 333		$ 100
Issuance of common stock upon exercise of pre-funded warrants (in shares)							10,832,122
Issuance of common stock upon exercise of pre-funded warrants							$ 1,083																		1,083
Stock-based compensation													490												490
Net loss																			(12,236)						(12,236)
Cumulative effect of adoption of new leases standard at Dec. 31, 2018																			(27)						(27)
Balances as of January 1, 2019, as adjusted at Dec. 31, 2018							$ 714						108,513						(98,016)						11,211
Issuance of common stock, net of offering costs (in shares)							1,200,000
Issuance of common stock, net of offering costs							$ 120						2,320												2,440
Reclassification of warrant to equity								$ 497		$ 333		$ 100								$ 497		$ 333		$ 100
Balances (in shares) at Sep. 30, 2019							46,223,594
Balances at Sep. 30, 2019							$ 4,622						124,533						(110,252)						18,903
Balances (in shares) at Jun. 30, 2019							15,785,735
Balances at Jun. 30, 2019							$ 1,579						119,258						(104,992)						15,845
Issuance of common stock and warrants, net of offering costs (in shares)			26,124,828
Issuance of common stock and warrants, net of offering costs			$ 2,612						4,632												7,244
Issuance of common stock warrants									497												497
Issuance of common stock upon exercise of pre-funded warrants (in shares)							4,313,031
Issuance of common stock upon exercise of pre-funded warrants							$ 431																		431
Stock-based compensation													146												146
Net loss																			(5,260)						(5,260)
Reclassification of warrant to equity									$ 497												$ 497
Balances (in shares) at Sep. 30, 2019							46,223,594
Balances at Sep. 30, 2019							$ 4,622						$ 124,533						$ (110,252)						$ 18,903

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
The September 2019 Offering [Member]
Offering costs from issuance of common stock and warrants	$ 1,457	$ 1,457
The April 2019 Offering [Member]
Offering costs from issuance of common stock and warrants		1,579
Offering costs		$ 560

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net loss	$ (12,236,000)	$ (13,105,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Bargain purchase gain		(6,660,000)
Depreciation and amortization	2,854,000	2,379,000
Impairment of intangible assets		1,600,000
Impairment of property and equipment		106,000
Stock-based compensation	490,000	387,000
Loss on revaluation of financial instruments		3,000
Non-cash interest expense	93,000	408,000
Amortization of note discount		18,000
Non-cash interest expense related to sale of future royalties	1,560,000	1,298,000
Non-cash revenue related to sale of future royalties	(3,147,000)	(18,000)
Change in operating assets and liabilities:
Accounts receivable	1,237,000	15,040,000
Prepaid expenses and other assets	164,000	(416,000)
Accounts payable	136,000	(3,495,000)
Accrued liabilities	(449,000)	(6,391,000)
Net cash used in operating activities	(9,298,000)	(8,846,000)
Cash flows from investing activities:
Purchase of property and equipment	(838,000)	(512,000)
Cash acquired in reverse merger		25,525,000
Cash paid for fractional shares in merger		(21,000)
Purchases of short-term investments		(573,000)
Proceeds from maturities of short-term investments		1,988,000
Net cash (used in) provided by investing activities	(838,000)	26,407,000
Cash flows from financing activities:
Net proceeds from issuance of common stock in registered direct offering	2,540,000
Repayment of principal on secured promissory note payable to Oxford Finance	(1,250,000)	(1,111,000)
Repayment of short-term note		(112,000)
Proceeds from issuance of common stock upon exercise of pre-funded warrants	1,083,000
Proceeds from issuance of common stock upon exercise of stock options		13,000
Net cash provided by (used in) financing activities	18,188,000	(1,210,000)
Net increase in cash and cash equivalents	8,052,000	16,351,000
Cash, cash equivalents and restricted cash at beginning of the period	11,506,000	1,571,000
Cash, cash equivalents and restricted cash at end of the period	19,558,000	17,922,000
Supplemental disclosure of cash flow information:
Interest paid	195,000	276,000
Supplemental disclosure of non-cash investing and financing activity:
Issuance of warrants to placement agents’ designees	100,000
Issuance of warrants to underwriters’ designees	830,000
Issuance of common stock upon reverse merger, net of cash paid for partial shares		31,768,000
Conversion of convertible promissory notes, related parties into common stock upon reverse merger		35,577,000
Reclassification of convertible preferred stock warrant liability to equity		70,000
Operating lease liabilities arising from obtaining right-of-use assets	1,929,000
Acquisition of property and equipment included in accounts payable	3,000	102,000
The April 2019 Offering [Member]
Cash flows from financing activities:
Net proceeds from issuance of common stock, pre-funded warrants and common warrants in underwritten offering	8,074,000
The September 2019 Offering [Member]
Cash flows from financing activities:
Net proceeds from issuance of common stock, pre-funded warrants and common warrants in underwritten offering	$ 7,741,000

Note 1 - Organization and Basis

Note 1 - Organization and Basis of Presentation	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1. Organization and Basis of Presentation General Vaxart Biosciences, Inc. was originally incorporated in California in March 2004, July 2007, On February 13, 2018, 0.22148 Immediately following the completion of the Merger, the Company effected a reverse stock split at a ratio of one eleven Immediately after the Reverse Stock Split there were approximately 7.1 51% 49% 0.0201346 On March 20, 2019, “March 2019 1,200,000 $3.0 $2.5 $320,000. 84,000 March 2019 one $3.125 five $100,000 10 On April 11, 2019, “April 2019 925,455 8,165,455 10,454,546 1,363,636 $1.10, $1.00, $0.10. one $0.10, one $1.10, five The total gross proceeds from the April 2019 $9.3 $8.1 September 30, 2019 $0.8 8,165,455 April 2019 Pursuant to the terms of an underwriting agreement, the Company paid the underwriters aggregate commissions and reimbursable costs of $750,000. 636,364 April 2019 one $1.375 five $333,000 10 On September 30, 2019, “September 2019 26,124,828 3,558,161 4,000,000 4,100,000 30,666,667 4,000,000 $0.30, $0.20, $0.10. one $0.10, may one $0.30, five The total gross proceeds from the September 2019 $8.7 $7.7 September 30, 2019, $0.3 1,433,333 Pursuant to the terms of an underwriting agreement, the Company paid the underwriters aggregate commissions and reimbursable costs of $713,000. 2,115,738 September 2019 one $0.375 five $497,000 10 The Company’s principal operations are based in South San Francisco, California, and it operates in one Liquidity and Going Concern Since incorporation, the Company has been involved primarily in performing research and development activities, hiring personnel, and raising capital to support these activities. The Company has experienced losses and negative cash flows from operations since its inception. As of September 30, 2019 110.3 $2.5 November 4, 2019 ( 8 13 The Company expects to incur increasing costs as research and clinical trials are advanced and, therefore, expects to continue to incur losses and negative operating cash flows for the next several years. Absent additional funding or adjustments to currently planned operating activities, management believes that the Company’s cash and cash equivalents of $ 19.6 September 30, 2019 not third 2020. The Company reviews its operations and clinical plans on a continuing basis, including its commitments for upcoming clinical trials. The Company plans to finance its operations with royalty revenue on sales of Inavir, additional equity or debt financing arrangements, and potentially with additional funding from government contracts or strategic alliances with partner companies. The availability and amount of such funding is not The uncertainties inherent in the Company’s future operations and in its ability to obtain additional funding raise substantial doubt about its ability to continue as a going concern beyond one not While management believes its plan to raise additional funds will alleviate the conditions that raise substantial doubt, these plans are not not may may

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 2. Basis of Presentation December 31, 2018, 10 February 6, 2019 ( no 2 not Basis of Consolidation Use of Estimates Concentration of Credit Risk not The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any one no L eases January 1, 2019, one not not Recent ly Adopted Accounting Pronouncements In February 2016, 2016 02, Leases (Topic 842 January 1, 2019, 2018 11, Leases (Topic 842 Ta July 2018, 2019 01, Leases (Topic 842 March 2019, not one not The adoption of this standard had a material effect on the Company’s condensed consolidated balance sheets, the most significant effects being the recognition of new right-of-use assets and lease liabilities. The Company recognized lease liabilities of $1,229,000, $783,000 $953,000 $249,000, $111,000 $27,000 The increase in accumulated deficit arose because the right-of-use asset impairment charge that would have been recorded in the three December 31, 2018, 842 no Recent Accounting Pronouncements The Company has reviewed all newly-issued accounting pronouncements and concluded that they either are not no

Note 3 - Fair Value of Financia

Note 3 - Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 3 . Fair Value of Financial Instruments Fair value accounting is applied for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Financial instruments include cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued liabilities that approximate fair value due to their relatively short maturities. As short-term investments are classified as held-to-maturity, they are recorded at their amortized cost. Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with inputs used to measure their fair values. The accounting guidance for fair value provides a framework for measuring fair value and requires certain disclosures about how fair value is determined. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance also establishes a three The three Level 1 Level 2 not Level 3 no The Company’s money market funds are classified within Level 1 3 The Company’s only recurring financial assets that are measured at fair value were $15,000 September 30, 2019 December 31, 2018, no nine September 30, 2019 3 nine September 30, 2018 Convertible Preferred Stock Warrant Liability Total (in thousands) Balance at January 1, 2018 $ 67 $ 67 Issuances — — Revaluation loss included in loss on revaluation of financial instruments, net 3 3 Settlements (70 ) (70 ) Balance at September 30, 2018 $ — $ — Total losses included in other income and (expenses) attributable to liabilities still held as of September 30, 2018 $ — $ — VAXART , INC. AND SUBSIDIARIES Notes to the Condensed Consolidated Financial Statements (Unaudited)

Note 4 - Balance Sheet Componen

Note 4 - Balance Sheet Components	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	NOTE 4 . Balance Sheet Components (a) Cash and Cash Equivalents Cash and cash equivalents comprises the following: September 30, 2019 December 31, 2018 (in thousands) Cash at banks $ 19,543 $ 11,441 Restricted cash — 50 Money market funds 15 15 Total cash and cash equivalents $ 19,558 $ 11,506 (b) Accounts Receivable Accounts receivable comprises the following: September 30, 2019 December 31, 2018 (in thousands) Royalties receivable $ 335 $ 1,776 Customer service contracts - billed 204 — Government contract - billed 20 20 Accounts receivable $ 559 $ 1,796 The Company has provided no September 30, 2019 December 31, 2018 (c) Property and Equipment, Net Property and equipment, net consists of the following: September 30, 2019 December 31, 2018 (in thousands) Laboratory equipment $ 2,854 $ 2,076 Office and computer equipment 231 227 Leasehold improvements 340 333 Total property and equipment 3,425 2,636 Less: accumulated depreciation (1,956 ) (1,570 ) Property and equipment, net $ 1,469 $ 1,066 Depreciation expense was $131,000 $130,000 three September 30, 2019 2018 $386,000 $349,000 nine September 30, 2019 2018 November 2018 7 September 30, 2018, $106,000 (d) Right-of-Use Assets , Net Right-of-use assets, net consists of the following: September 30, 2019 (in thousands) Facilities $ 2,294 Office equipment 7 Right-of-use assets, net $ 2,301 (e) Intangible Assets Intangible assets comprise developed technology, intellectual property and, until it was considered fully impaired, in-process research and development. Intangible assets are carried at cost less accumulated amortization. Amortization is computed using the straight-line method over useful lives ranging from 1.3 11.75 20 September 30, 2019 December 31, 2018 (in thousands) Purchased technology $ 22,100 $ 22,100 Intellectual property 80 80 Total cost 22,180 22,180 Less: accumulated amortization (4,654 ) (2,767 ) Intangible assets, net $ 17,526 $ 19,413 Intangible asset amortization expense was $433,000 $812,000 three September 30, 2019 2018 $1,887,000 $2,030,000 nine September 30, 2019 2018 2 June 2018, three June 30, 2018, $1.6 1 As of September 30, 2019 Year Ending December 31, Amount 2019 (three months remaining) $ 433 2020 1,732 2021 1,732 2022 1,732 2023 1,731 Thereafter 10,166 Total $ 17,526 (f) Accrued Liabilities Accrued liabilities consist of the following: September 30, 2019 December 31, 2018 (in thousands) Accrued compensation $ 1,027 $ 632 Accrued clinical and manufacturing expenses 7 75 Accrued professional and consulting services 35 166 Reserve for return of royalties 178 339 Deferred revenue 110 — Deferred rent and lease loss accrual, current portion — 111 Other liabilities, current portion 246 195 Total $ 1,603 $ 1,518

Note 5 - Revenue

Note 5 - Revenue	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Revenue [Text Block]	NOTE 5 . Revenue Service Contracts with Customers Revenue Recognition. $94,000 three September 30, 2019 first Contract Balances. $204,000 September 30, 2019. no December 31, 2018. no Remaining Performance Obligations. September 30, 2019, $523,000, $110,000 4 $413,000 not 100% not not Government Contract In September 2015, May 25 July 18, 2017, June 28, 2018, $14 $1.7 September 30, 2018. $15.7 $194,000 $1,324,000 three nine September 30, 2018, December 31, 2018, no Billings under the contract were based on approved provisional indirect billing rates, which permit recovery of fringe benefits, overhead and general and administrative expenses. Indirect rates as well as allowable costs are subject to audit by HHS BARDA on an annual basis. Management believes that revenues recognized to date have been recorded in amounts that are expected to be realized upon final audit and settlement. When the final determination of the allowable costs for any year has been made, revenue and billings may not Royalty Agreements Aviragen entered into a royalty-bearing research and license agreement with GlaxoSmithKline, plc (“GSK”) in 1990 July 2019 $8,000 three September 30, 2019 $87,000 three September 30, 2018 nine September 30, 2019 nine September 30, 2018 $772,000 $498,000, 7% The Company also generates royalty revenue from the sale of Inavir in Japan, pursuant to a collaboration and license agreement that Aviragen entered into with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) in 2009. September 2010, 4% December 2029, nine September 30, 2019 nine September 30, 2018, $2,964,000 $552,000, 4% No three September 30, 2019 $335,000, 6 three September 30, 2018 no 5% $17,000 three September 30, 2019 $254,000 $29,000 nine September 30, 2019 2018 The Company’s royalty revenue is seasonal, in line with the flu season. The majority of the Company’s royalty revenue is earned in the first fourth

Note 6 - Liabilities Related to

Note 6 - Liabilities Related to Sale of Future Royalties	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Liabilities Related to Sale of Future Royalties [Text Block]	NOTE 6 . Liabilities Related to Sale of Future Royalties In April 2016, $20.0 first $3.0 15% $1.0 April 1, Under the relevant accounting guidance, due to a limit on the amount of royalties that HCRP can earn under the RIAA, this transaction is accounted for as a liability that is being amortized using the interest method over the life of the arrangement. The Company has no not not The following table shows the activity within the liability account in the nine September 30, 2019 Total liability related to sale of future royalties, start of period $ 17,741 Non-cash royalty revenue paid to HCRP (3,147 ) Non-cash interest expense recognized 1,560 Total liability related to sale of future royalties, end of period 16,154 Current portion (3,228 ) Long-term portion $ 12,926

Note 7 - Leases

Note 7 - Leases	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	NOTE 7 . Leas es The Company has obtained the right of use for office and manufacturing facilities under five one three one three one The Company obtained the right of use of real estate located in South San Francisco, California, in June 2015 April 30, 2020, five July 2019, April 30, 2025. February 2018 February 28, 2021, no November 30, 2018. three two July 31, 2021 one November 30, 2019, no three October 2019 September 2021. As of September 30, 2019 one 10.53% 3.82 The following table summarizes the Company’s undiscounted cash payment obligations for its operating lease liabilities with initial terms of more than twelve September 30, 2019 Year Ending December 31, 2019 (excluding the nine months ended September 30, 2019) $ 264 2020 1,024 2021 620 2022 336 2023 348 Thereafter 482 Undiscounted total 3,074 Less: imputed interest (560 ) Present value of future minimum payments 2,514 Current portion of operating lease liability (820 ) Operating lease liability, net of current portion $ 1,694 The Company presently has no no one Certain operating lease agreements for facilities include non-lease costs, such as common area maintenance, which are recorded as variable lease costs. Operating lease expenses for the three nine September 30, 2019 Three Months Ended Nine Months Ended September 30, 2019 September 30, 2019 Lease cost (in thousands) Operating lease cost $ 258 $ 703 Short-term lease cost 4 11 Variable lease cost 44 132 Sublease income (53 ) (162 ) Total lease cost $ 253 $ 684 Net cash outflows associated with operating leases totaled $253,000 $740,000 three nine September 30, 2019 $255,000 $623,000 three nine September 30, 2018 Future minimum payments and sublease income under operating leases as of December 31, 2018, Year Ending December 31, Lease Payments Sublease Income (in thousands) 2019 $ 859 $ 213 2020 411 219 2021 56 38 Thereafter — — Total $ 1,326 $ 470

Note 8 - Secured Promissory Not

Note 8 - Secured Promissory Note Payable to Oxford Finance	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Secured Promissory Note Payable [Text Block]	NOTE 8 . Secured Promissory Note Payable to Oxford Finance On December 22, 2016, $5.0 $5.0 30 6.17%, four first 12 36 $325,000 In connection with the Loan Agreement, the Company issued a warrant to Oxford Finance to purchase 7,563 $33.11 December 2026. $134,000, 10.5%. $82,000 $128,000 three September 30, 2019 2018 $55,000 $87,000 $284,000 $407,000 nine September 30, 2019 2018 $191,000 $276,000 The Warrant provided that if the share price at the next equity financing was less than the Warrant exercise price, then the Warrant would be for the new class of shares, the exercise price would be the new class share price, and the number of shares would be calculated by dividing $250,000 Due to the antidilution protection, following the Merger, the Warrant was amended to allow the holder to purchase 10,914 $22.99 no $70,000 February 13, 2018, The outstanding balance of this loan, including the additional final payment of $325,000, November 4, 2019 ( 13

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 9 . Commitments and Contingencies (a) Leases The Company’s lease commitments are detailed in Note 7. (b) Indemnifications In the ordinary course of business, the Company enters into agreements that may may third not may may (c) Litigation From time to time the Company may not may

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 1 0 . Stock holders’ Equity (a) P referred Stock The Company is authorized to issue 5,000,000 $0.10 may, 5,000,000 one may No no (b) Common Stock On April 23, 2019, $0.10, 200,000,000 100,000,000 April 23, 2019, one may no September 30, 2019 no In the event of the Company’s voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the common stock will be entitled to receive an equal amount per share of all of the Company’s assets of whatever kind available for distribution to stockholders, after the rights of the holders of the preferred stock have been satisfied. There are no The Company had shares of common stock reserved for issuance as follows: September 30, 2019 December 31, 2018 Options issued and outstanding 1,862,002 865,163 Available for future grants of equity awards 351,428 223,377 Common stock warrants 45,401,562 10,914 Total 47,614,992 1,099,454 (c) Warrants The Company has the following warrants outstanding as of September 30, 2019 none Securities into which warrants are convertible Warrants outstanding Exercise Price Expiration Date Common Stock 1,433,333 $ 0.10 September 2024 Common Stock 30,666,667 $ 0.30 September 2024 Common Stock 2,115,738 $ 0.375 September 2024 Common Stock 10,454,546 $ 1.10 April 2024 Common Stock 636,364 $ 1.375 April 2024 Common Stock 84,000 $ 3.125 March 2024 Common Stock 10,914 $ 22.99 December 2026 Total 45,401,562 The aggregate fair value at issuance of the warrants entitling the holder to purchase one $3.125 March 2019 1 $100,000, $2.08 80%, 2.34%, zero 5.0 one $1.375 April 2019 1 $333,000, $0.89 83%, 2.31%, zero 5.0 one $0.375 September 2019 1 $497,000, $0.36 83%, 1.55%, zero 5.0 In the event of a Fundamental Transaction (a transfer of ownership of the Company as defined in the warrant) within the Company’s control, the holders of the unexercised common stock warrants exercisable for $0.30, $0.375 $1.10 not

Note 11 - Equity Incentive Plan

Note 11 - Equity Incentive Plans	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	NOTE 1 1 . Equity Incentive Plan s Prior to the Merger, Private Vaxart issued equity awards for compensation purposes to employees, directors and consultants under its 2007 “2007 2007 July 2017 no may 2007 In November 2016, 2016 “2016 2016 Under the 2016 2016 ten may 2019 “2019 no 2016 On April 23, 2019, 2019 may 2019 may The aggregate number of shares of common stock that may 2019 not 1,600,000 2019 ten may A summary of stock option transactions in the nine September 30, 2019 Weighted Shares Number of Average Available Options Exercise For Grant Outstanding Price Balance at January 1, 2019 200,650 865,163 $ 8.13 Authorized under 2019 Plan 1,600,000 — $ — Removed from 2016 Plan (223,389 ) — $ — Granted (1,413,590 ) 1,413,590 $ 0.76 Forfeited 165,018 (212,731 ) $ 1.77 Canceled 22,739 (204,020 ) $ 9.15 Balance at September 30, 2019 351,428 1,862,002 $ 3.15 The weighted average grant date fair value of options awarded in the nine September 30, 2019 2018 $0.55 $3.59, Nine Months Ended September 30, 2019 2018 Risk-free interest rate 1.89% - 2.31% 2.79% - 2.80% Expected term 5.39 - 6.08 Years 5.84 - 6.05 Years Expected volatility 83% - 85% 78% - 80% Dividend yield — % — % The Company measures the fair value of all stock-based awards on the grant date and records the fair value of these awards, net of estimated forfeitures, to compensation expense over the service period. Total stock-based compensation recognized for options was as follows: Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 (in thousands) (in thousands) Research and development $ 63 $ 92 $ 222 $ 195 General and administrative 83 91 268 192 Total stock-based compensation $ 146 $ 183 $ 490 $ 387 As of September 30, 2019 $1.1 2.61

Note 12 - Net Loss Per Share At

Note 12 - Net Loss Per Share Attributable to Common Stockholders	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 1 2 . Net Loss Per Share Attributable to Common Stockholders The following table presents the calculation of basic and diluted net loss per share (in thousands, except share and per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Net loss $ (5,260 ) $ (6,548 ) $ (12,236 ) $ (13,105 ) Series B and C preferred dividend — — — (339 ) Net loss attributable to common stockholders – diluted calculation $ (5,260 ) $ (6,548 ) $ (12,236 ) $ (13,444 ) Shares used to compute net loss per share – basic and diluted 16,249,032 7,141,189 12,748,665 6,038,001 Net loss per share – basic and diluted $ (0.32 ) $ (0.92 ) $ (0.96 ) $ (2.23 ) No The following potentially dilutive securities were excluded from the computation of diluted weighted average shares outstanding because they would have been antidilutive: Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Options to purchase common stock 1,965,910 978,495 1,466,495 802,885 Warrants to purchase common stock 13,064,514 10,914 8,340,589 9,195 Warrant to purchase convertible preferred stock — — — 1,191 Series B and C convertible preferred stock outstanding, including cumulative dividends — — — 285,797 Series A convertible preferred stock outstanding — — — 16,391 Convertible promissory notes, related party (as converted) — — — 247,557 Total potentially dilutive securities excluded from denominator of the diluted earnings per share computation 15,030,424 989,409 9,807,084 1,363,016

Note 13 - Subsequent Events

Note 13 - Subsequent Events	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 13 . Subsequent Events The secured promissory note payable to Oxford Finance (see Note 8 November 4, 2019. $0.1 three December 31, 2019.

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation December 31, 2018, 10 February 6, 2019 ( no 2 not
Consolidation, Policy [Policy Text Block]	Basis of Consolidation
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk not The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any one no
Lessee, Leases [Policy Text Block]	L eases January 1, 2019, one not not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent ly Adopted Accounting Pronouncements In February 2016, 2016 02, Leases (Topic 842 January 1, 2019, 2018 11, Leases (Topic 842 Ta July 2018, 2019 01, Leases (Topic 842 March 2019, not one not The adoption of this standard had a material effect on the Company’s condensed consolidated balance sheets, the most significant effects being the recognition of new right-of-use assets and lease liabilities. The Company recognized lease liabilities of $1,229,000, $783,000 $953,000 $249,000, $111,000 $27,000 The increase in accumulated deficit arose because the right-of-use asset impairment charge that would have been recorded in the three December 31, 2018, 842 no Recent Accounting Pronouncements The Company has reviewed all newly-issued accounting pronouncements and concluded that they either are not no

Note 3 - Fair Value of Financ_2

Note 3 - Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Convertible Preferred Stock Warrant Liability Total (in thousands) Balance at January 1, 2018 $ 67 $ 67 Issuances — — Revaluation loss included in loss on revaluation of financial instruments, net 3 3 Settlements (70 ) (70 ) Balance at September 30, 2018 $ — $ — Total losses included in other income and (expenses) attributable to liabilities still held as of September 30, 2018 $ — $ —

Note 4 - Balance Sheet Compon_2

Note 4 - Balance Sheet Components (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Cash and Cash Equivalents [Table Text Block]	September 30, 2019 December 31, 2018 (in thousands) Cash at banks $ 19,543 $ 11,441 Restricted cash — 50 Money market funds 15 15 Total cash and cash equivalents $ 19,558 $ 11,506
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	September 30, 2019 December 31, 2018 (in thousands) Royalties receivable $ 335 $ 1,776 Customer service contracts - billed 204 — Government contract - billed 20 20 Accounts receivable $ 559 $ 1,796
Property, Plant and Equipment [Table Text Block]	September 30, 2019 December 31, 2018 (in thousands) Laboratory equipment $ 2,854 $ 2,076 Office and computer equipment 231 227 Leasehold improvements 340 333 Total property and equipment 3,425 2,636 Less: accumulated depreciation (1,956 ) (1,570 ) Property and equipment, net $ 1,469 $ 1,066
Lessee, Operating Lease, Right-of-Use Assets [Table Text Block]	September 30, 2019 (in thousands) Facilities $ 2,294 Office equipment 7 Right-of-use assets, net $ 2,301
Schedule of Finite-Lived Intangible Assets [Table Text Block]	September 30, 2019 December 31, 2018 (in thousands) Purchased technology $ 22,100 $ 22,100 Intellectual property 80 80 Total cost 22,180 22,180 Less: accumulated amortization (4,654 ) (2,767 ) Intangible assets, net $ 17,526 $ 19,413
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year Ending December 31, Amount 2019 (three months remaining) $ 433 2020 1,732 2021 1,732 2022 1,732 2023 1,731 Thereafter 10,166 Total $ 17,526
Schedule of Accrued Liabilities [Table Text Block]	September 30, 2019 December 31, 2018 (in thousands) Accrued compensation $ 1,027 $ 632 Accrued clinical and manufacturing expenses 7 75 Accrued professional and consulting services 35 166 Reserve for return of royalties 178 339 Deferred revenue 110 — Deferred rent and lease loss accrual, current portion — 111 Other liabilities, current portion 246 195 Total $ 1,603 $ 1,518

Note 6 - Liabilities Related _2

Note 6 - Liabilities Related to Sale of Future Royalties (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	Total liability related to sale of future royalties, start of period $ 17,741 Non-cash royalty revenue paid to HCRP (3,147 ) Non-cash interest expense recognized 1,560 Total liability related to sale of future royalties, end of period 16,154 Current portion (3,228 ) Long-term portion $ 12,926

Note 7 - Leases (Tables)

Note 7 - Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year Ending December 31, 2019 (excluding the nine months ended September 30, 2019) $ 264 2020 1,024 2021 620 2022 336 2023 348 Thereafter 482 Undiscounted total 3,074 Less: imputed interest (560 ) Present value of future minimum payments 2,514 Current portion of operating lease liability (820 ) Operating lease liability, net of current portion $ 1,694
Lease, Cost [Table Text Block]	Three Months Ended Nine Months Ended September 30, 2019 September 30, 2019 Lease cost (in thousands) Operating lease cost $ 258 $ 703 Short-term lease cost 4 11 Variable lease cost 44 132 Sublease income (53 ) (162 ) Total lease cost $ 253 $ 684
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year Ending December 31, Lease Payments Sublease Income (in thousands) 2019 $ 859 $ 213 2020 411 219 2021 56 38 Thereafter — — Total $ 1,326 $ 470

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Common Stock Reserved for Issuance [Table Text Block]	September 30, 2019 December 31, 2018 Options issued and outstanding 1,862,002 865,163 Available for future grants of equity awards 351,428 223,377 Common stock warrants 45,401,562 10,914 Total 47,614,992 1,099,454
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Securities into which warrants are convertible Warrants outstanding Exercise Price Expiration Date Common Stock 1,433,333 $ 0.10 September 2024 Common Stock 30,666,667 $ 0.30 September 2024 Common Stock 2,115,738 $ 0.375 September 2024 Common Stock 10,454,546 $ 1.10 April 2024 Common Stock 636,364 $ 1.375 April 2024 Common Stock 84,000 $ 3.125 March 2024 Common Stock 10,914 $ 22.99 December 2026 Total 45,401,562

Note 11 - Equity Incentive Pl_2

Note 11 - Equity Incentive Plans (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Shares Number of Average Available Options Exercise For Grant Outstanding Price Balance at January 1, 2019 200,650 865,163 $ 8.13 Authorized under 2019 Plan 1,600,000 — $ — Removed from 2016 Plan (223,389 ) — $ — Granted (1,413,590 ) 1,413,590 $ 0.76 Forfeited 165,018 (212,731 ) $ 1.77 Canceled 22,739 (204,020 ) $ 9.15 Balance at September 30, 2019 351,428 1,862,002 $ 3.15
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Nine Months Ended September 30, 2019 2018 Risk-free interest rate 1.89% - 2.31% 2.79% - 2.80% Expected term 5.39 - 6.08 Years 5.84 - 6.05 Years Expected volatility 83% - 85% 78% - 80% Dividend yield — % — %
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 (in thousands) (in thousands) Research and development $ 63 $ 92 $ 222 $ 195 General and administrative 83 91 268 192 Total stock-based compensation $ 146 $ 183 $ 490 $ 387

Note 12 - Net Loss Per Share _2

Note 12 - Net Loss Per Share Attributable to Common Stockholders (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Net loss $ (5,260 ) $ (6,548 ) $ (12,236 ) $ (13,105 ) Series B and C preferred dividend — — — (339 ) Net loss attributable to common stockholders – diluted calculation $ (5,260 ) $ (6,548 ) $ (12,236 ) $ (13,444 ) Shares used to compute net loss per share – basic and diluted 16,249,032 7,141,189 12,748,665 6,038,001 Net loss per share – basic and diluted $ (0.32 ) $ (0.92 ) $ (0.96 ) $ (2.23 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Options to purchase common stock 1,965,910 978,495 1,466,495 802,885 Warrants to purchase common stock 13,064,514 10,914 8,340,589 9,195 Warrant to purchase convertible preferred stock — — — 1,191 Series B and C convertible preferred stock outstanding, including cumulative dividends — — — 285,797 Series A convertible preferred stock outstanding — — — 16,391 Convertible promissory notes, related party (as converted) — — — 247,557 Total potentially dilutive securities excluded from denominator of the diluted earnings per share computation 15,030,424 989,409 9,807,084 1,363,016

Note 1 - Organization and Bas_2

Note 1 - Organization and Basis of Presentation (Details Textual)	Sep. 30, 2019USD ($)$ / sharesshares	Apr. 11, 2019USD ($)$ / sharesshares	Mar. 20, 2019USD ($)$ / sharesshares	Feb. 13, 2018shares	Sep. 30, 2019USD ($)$ / sharesshares	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)
Conversion of Stock, Shares Issued				0.22148
Stock Issued During Period, Shares, Reverse Stock Splits				7,100,000
Exchange Ratio, Number of Shares Exchanged Per Share				0.0201346
Stock Issued During Period, Shares, New Issues			1,200,000
Gross Proceeds from Issuance of Common Stock | $			$ 3,000,000
Proceeds from Issuance of Common Stock | $			2,500,000		$ 2,540,000
Payments of Stock Issuance Costs | $			$ 320,000
Proceeds from Warrant Exercises | $					$ 1,083,000
Class of Warrant or Right, Outstanding	45,401,562				45,401,562
Payments for Aggregate Commissions to Underwriters | $		$ 750,000
Number of Reportable Segments					1
Retained Earnings (Accumulated Deficit), Ending Balance | $	$ (110,252,000)				$ (110,252,000)		$ (97,989,000)
Notes Payable, Total | $	2,500,000				2,500,000
Cash and Cash Equivalents, at Carrying Value, Ending Balance | $	$ 19,600,000				19,600,000
The April 2019 Offering [Member]
Stock Issued During Period, Shares, New Issues, Excluding Shares Sold to Underwriters		925,455
Shares Issued, Price Per Share | $ / shares		$ 1.10
Proceeds from Issuance or Sale of Equity, Total | $		$ 9,300,000
Net Proceeds from Issuance of Common Stock, Pre-funded Warrants and Common Warrants in Underwritten Offering | $		$ 8,100,000			$ 8,074,000
The September 2019 Offering [Member]
Stock Issued During Period, Shares, New Issues, Excluding Shares Sold to Underwriters	26,124,828
Shares Issued, Price Per Share | $ / shares	$ 0.30				$ 0.30
Pre-funded Warrant Price | $ / shares	0.20				0.20
Pre-funded Warrant, Accompanying Warrant, Amount Paid Per Share | $ / shares	$ 0.10				$ 0.10
Proceeds from Issuance or Sale of Equity, Total | $	$ 8,700,000
Net Proceeds from Issuance of Common Stock, Pre-funded Warrants and Common Warrants in Underwritten Offering | $	7,700,000				$ 7,741,000
Payments for Aggregate Commissions to Underwriters | $	$ 713,000
Warrants in Connection with March 2019 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			84,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 3.125
Warrants and Rights Outstanding, Term			5 years
Warrants and Rights Outstanding | $			$ 100,000
Warrants in Connection With the April 2019 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		10,454,546
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 1.375
Warrants and Rights Outstanding | $		$ 333,000
Class of Warrant Right, Number of Pre-funded Warrants Issued During Period		8,165,455
Pre-funded Warrant Price | $ / shares		$ 1
Pre-funded Warrant, Accompanying Warrant, Amount Paid Per Share | $ / shares		$ 0.10
Proceeds from Warrant Exercises | $					$ 800,000
Warrants in Connection With the April 2019 Offering [Member] | Over-Allotment Option [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,363,636
Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1	1			1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.10	$ 0.10			$ 0.10
Class of Warrant Right, Number of Pre-funded Warrants Issued During Period	4,100,000
Class of Warrant or Right, Outstanding	8,165,455				8,165,455
Common Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1	1			1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.30	$ 1.10			$ 0.30
Warrants and Rights Outstanding, Term	5 years	5 years			5 years
Underwriter Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 1.375
Class of Warrant or Right, Issued During Period		636,364
Class of Warrant or Right, Period to Expiration		5 years
Class of Warrant or Right, Issued During Period, Fair Value | $		$ 333,000
Warrants in Connection with the September 2019 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	30,666,667				30,666,667
Proceeds from Warrant Exercises | $	$ 300,000
Class of Warrant or Right, Outstanding	1,433,333				1,433,333
Class of Warrant or Right, Exercised During Period	3,558,161
Warrants in Connection with the September 2019 Offering [Member] | Over-Allotment Option [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	4,000,000				4,000,000
Underwriter Warrants, September 2019 [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1				1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.375				$ 0.375
Warrants and Rights Outstanding | $	$ 497,000				$ 497,000
Class of Warrant or Right, Issued During Period	2,115,738
Class of Warrant or Right, Period to Expiration	5 years
Private Vaxart's Stockholders, Warrantholders, and Optionholders [Member]
Ownership Percentage				51.00%
Aviragens Stockholderrs and Optionholders [Member]
Ownership Percentage				49.00%
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio				11

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	Sep. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
Operating Lease, Liability, Total	$ 2,514,000
Operating Lease, Liability, Current	820,000
Operating Lease, Right-of-Use Asset	2,301,000
Deferred Rent Credit, Current			111,000
Retained Earnings (Accumulated Deficit), Ending Balance	$ (110,252,000)		$ (97,989,000)
Accounting Standards Update 2016-02 [Member]
Operating Lease, Liability, Total		$ 1,229,000
Operating Lease, Liability, Current		783,000
Operating Lease, Right-of-Use Asset		953,000
Deferred Rent Credit		(249,000)
Deferred Rent Credit, Current		(111,000)
Retained Earnings (Accumulated Deficit), Ending Balance		$ (27,000)

Note 3 - Fair Value of Financ_3

Note 3 - Fair Value of Financial Instruments (Details Textual) - Fair Value, Recurring [Member] - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Financial Liabilities Fair Value Disclosure, Total	$ 0	$ 0
Money Market Funds [Member]
Cash and Cash Equivalents, Fair Value Disclosure	$ 15,000	$ 15,000

Note 3 - Fair Value of Financ_4

Note 3 - Fair Value of Financial Instruments - a Reconciliation of All Liabilities Measured At Fair Value On a Recurring Basis Using Significant Unobservable Inputs (Level 3) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2018USD ($)
Balance at January 1, 2018	$ 67
Issuances
Revaluation loss included in loss on revaluation of financial instruments, net	3
Settlements	(70)
Balance at September 30, 2018
Total losses included in other income and (expenses) attributable to liabilities still held as of September 30, 2018
Convertible Preferred Stock Warrant Liability [Member]
Balance at January 1, 2018	67
Issuances
Revaluation loss included in loss on revaluation of financial instruments, net	3
Settlements	(70)
Balance at September 30, 2018
Total losses included in other income and (expenses) attributable to liabilities still held as of September 30, 2018

Note 4 - Balance Sheet Compon_3

Note 4 - Balance Sheet Components (Details Textual) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Jun. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Accounts Receivable, Allowance for Credit Loss, Current	$ 0			$ 0		$ 0
Depreciation, Total	131,000	$ 130,000		386,000	$ 349,000
Impairment of Property and Equipment		106,000			106,000
Amortization of Intangible Assets, Total	433,000	812,000		1,887,000	2,030,000
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)					$ 1,600,000
In Process Research and Development 1 [Member]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)			$ 1,600,000
Intellectual Property [Member]
Finite-Lived Intangible Asset, Useful Life				20 years
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life				1 year 109 days
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life				11 years 273 days

Note 4 - Balance Sheet Compon_4

Note 4 - Balance Sheet Components - Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2017
Cash at banks	$ 19,543	$ 11,441
Restricted cash		50
Money market funds	15	15
Total cash and cash equivalents	$ 19,558	$ 11,506	$ 17,922	$ 1,571

Note 4 - Balance Sheet Compon_5

Note 4 - Balance Sheet Components - Accounts Receivable, Net of Allowance (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Accounts receivable	$ 559	$ 1,796
Royalty [Member]
Accounts receivable	335	1,776
Customer Service Contracts [Member]
Accounts receivable	204
Government Contract [Member]
Accounts receivable	$ 20	$ 20

Note 4 - Balance Sheet Compon_6

Note 4 - Balance Sheet Components - Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Property and equipment, gross	$ 3,425	$ 2,636
Less: accumulated depreciation	(1,956)	(1,570)
Property and equipment, net	1,469	1,066
Laboratory Equipment [Member]
Property and equipment, gross	2,854	2,076
Office Equipment [Member]
Property and equipment, gross	231	227
Leasehold Improvements [Member]
Property and equipment, gross	$ 340	$ 333

Note 4 - Balance Sheet Compon_7

Note 4 - Balance Sheet Components - Right-of-Use Assets, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Right-of-use assets, net	$ 2,301
Facilities [Member]
Right-of-use assets, net	2,294
Office Equipment [Member]
Right-of-use assets, net	$ 7

Note 4 - Balance Sheet Compon_8

Note 4 - Balance Sheet Components - Intangible assets (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Intangible assets, gross	$ 22,180	$ 22,180
Less: accumulated amortization	(4,654)	(2,767)
Intangible assets, net	17,526	19,413
Purchased Technology [Member]
Intangible assets, gross	22,100	22,100
Intellectual Property [Member]
Intangible assets, gross	$ 80	$ 80

Note 4 - Balance Sheet Compon_9

Note 4 - Balance Sheet Components - Estimated Future Amortization Expense (Details) $ in Thousands	Sep. 30, 2019USD ($)
2019 (three months remaining)	$ 433
2020	1,732
2021	1,732
2022	1,732
2023	1,731
Thereafter	10,166
Total	$ 17,526

Note 4 - Balance Sheet Compo_10

Note 4 - Balance Sheet Components - Accrued liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Accrued compensation	$ 1,027	$ 632
Accrued clinical and manufacturing expenses	7	75
Accrued professional and consulting services	35	166
Reserve for return of royalties	178	339
Deferred revenue	110
Deferred rent and lease loss accrual, current portion		111
Other liabilities, current portion	246	195
Total	$ 1,603	$ 1,518

Note 5 - Revenue 1 (Details Tex

Note 5 - Revenue 1 (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		37 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Jun. 28, 2018	Dec. 31, 2018	Sep. 30, 2015
Revenue from Contract with Customer, Including Assessed Tax	$ 454,000	$ 281,000	$ 5,946,000	$ 2,392,000
Contract with Customer, Asset, Net, Current, Total	204,000		204,000			$ 0
Contract With Customer, Asset, Revenue Recognized	0		0			$ 0
Revenue, Remaining Performance Obligation, Not Recorded on Balance Sheet	413,000		413,000
Income Tax Expense (Benefit), Total	31,000		$ 294,000	29,000
Foreign Tax Authority [Member] | National Tax Agency, Japan [Member]
Royalty Withholding Tax			5.00%
Income Tax Expense (Benefit), Total	17,000			29,000
Customer Service Contracts [Member]
Revenue from Contract with Customer, Including Assessed Tax	94,000		$ 94,000
Government Contract [Member]
Revenue from Contract with Customer, Including Assessed Tax		194,000		1,324,000
Contract Value					$ 15,700,000		$ 14,000,000
Contract Value, Adjustment					$ 1,700,000
Revenues, Total		194,000		1,324,000
Royalty [Member]
Revenue from Contract with Customer, Including Assessed Tax	8,000	87,000	3,736,000	1,050,000
Royalty [Member] | GSK Research and License Agreement [Member]
Revenue from Contract with Customer, Including Assessed Tax	8,000	87,000	$ 772,000	$ 498,000
Royalty Percentage			7.00%	7.00%
Royalty [Member] | Daiichi Sankyo Collaberation and License Agreement [Member]
Revenue from Contract with Customer, Including Assessed Tax	0	$ 0	$ 2,964,000	$ 552,000
Royalty Percentage			4.00%	4.00%
Royalty [Member] | Daiichi Sankyo Collaberation and License Agreement [Member] | HealthCare Royalty Partners III, L.P. [Member]
Liability Related to Sale of Future Royalties	$ 335,000		$ 335,000

Note 5 - Revenue 2 (Details Tex

Note 5 - Revenue 2 (Details Textual) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01	Sep. 30, 2019USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 523,000
Revenue, Remaining Performance Obligation, Percentage	100.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Accounts Payable and Accrued Liabilities [Member]
Contract with Customer, Liability, Total	$ 110,000

Note 6 - Liabilities Related _3

Note 6 - Liabilities Related to Sale of Future Royalties (Details Textual) - HCRP [Member] $ in Millions	1 Months Ended
	Apr. 30, 2016USD ($)
Proceeds from Sale of Future Royalties, Net	$ 20
Royalty Interest Due Each Year	$ 3
Royalty Interest, Percentage of Additional Royalties Due Each Year	15.00%
Royalty Interest, Additional Royalties Due Each Year	$ 1

Note 6 - Liabilities Related _4

Note 6 - Liabilities Related to Sale of Future Royalties - Deferred Revenue Activity (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Current portion	$ (3,228)	$ (3,328)
Long-term portion	12,926	$ 14,413
HealthCare Royalty Partners III, L.P. [Member] | Royalty Arrangement [Member]
Total liability related to sale of future royalties, start of period	17,741
Non-cash royalty revenue paid to HCRP	(3,147)
Non-cash interest expense recognized	1,560
Total liability related to sale of future royalties, end of period	16,154
Current portion	(3,228)
Long-term portion	$ 12,926

Note 7 - Leases (Details Textua

Note 7 - Leases (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Lessee, Operating Lease, Number of Right-of-Use Leases	5		5
Lessee, Operating Lease, Number of Right-of-Use Leases, Subleased	1		1
Lessee, Operating Lease, Number Leases Exceeding One Year	3		3
Lessee, Operating Lease, Number Leases Exceeding Less than One Year	3		3
Lessee, Operating Lease, Renewal Term	5 years		5 years
Operating Lease, Weighted Average Discount Rate, Percent	10.53%		10.53%
Operating Lease, Weighted Average Remaining Lease Term	3 years 299 days		3 years 299 days
Lessee, Finance Lease, Number of Leases	0		0
Short-term Lease Commitment, Amount	$ 0		$ 0
Operating Lease, Payments	$ 253,000	$ 255,000	$ 740,000	$ 623,000

Note 7 - Leases - Lease Liabili

Note 7 - Leases - Lease Liabilities Payment Obligations (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
2019 (excluding the nine months ended September 30, 2019)	$ 264
2020	1,024
2021	620
2022	336
2023	348
Thereafter	482
Undiscounted total	3,074
Less: imputed interest	(560)
Present value of future minimum payments	2,514
Current portion of operating lease liability	(820)
Operating lease liability, net of current portion	$ 1,694

Note 7 - Leases - Operating Lea

Note 7 - Leases - Operating Lease Expenses (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Operating lease cost	$ 258	$ 703
Short-term lease cost	4	11
Variable lease cost	44	132
Sublease income	(53)	(162)
Total lease cost	$ 253	$ 684

Note 7 - Leases - Minimum Payme

Note 7 - Leases - Minimum Payments and Sublease Income Under ASC 840 (Details) $ in Thousands	Dec. 31, 2018USD ($)
2019, lease payments	$ 859
2019, sublease income	213
2020, lease payments	411
2020, sublease income	219
2021, lease payments	56
2021, sublease income	38
Thereafter, lease payments
Thereafter, sublease income
Total, lease payments	1,326
Total, sublease income	$ 470

Note 8 - Secured Promissory N_2

Note 8 - Secured Promissory Note Payable to Oxford Finance (Details Textual) - USD ($)	Dec. 22, 2016	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Feb. 13, 2018
Debt Conversion, Converted Instrument, Amount					$ 35,577,000
Warrants in Connection with Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	7,563					10,914
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 33.11					$ 22.99
Warrants Not Settleable in Cash, Fair Value Disclosure	$ 134,000					$ 70,000
Loan Agreement [Member] | Oxford Finance [Member]
Long-term Debt, Gross	$ 5,000,000
Debt Instrument, Term	4 years
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid	$ 325,000
Debt Instrument, Interest Rate, Stated Percentage	10.50%
Interest Expense, Debt, Total		$ 82,000	$ 128,000	284,000	407,000
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total		$ 55,000	$ 87,000	$ 191,000	$ 276,000
Debt Conversion, Converted Instrument, Amount	$ 250,000
Loan Agreement [Member] | Oxford Finance [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	6.17%

Note 10 - Stockholders' Equit_2

Note 10 - Stockholders' Equity (Details Textual)	9 Months Ended
	Sep. 30, 2019USD ($)$ / sharesshares	Apr. 23, 2019$ / sharesshares	Apr. 22, 2019shares	Apr. 11, 2019USD ($)$ / sharesshares	Mar. 20, 2019USD ($)$ / sharesshares	Dec. 31, 2018$ / sharesshares
Preferred Stock, Shares Authorized | shares	5,000,000					5,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.10					$ 0.10
Preferred Stock, Shares Outstanding, Ending Balance | shares	0					0
Common Stock, Par or Stated Value Per Share	$ 0.10	$ 0.10				$ 0.10
Common Stock, Shares Authorized | shares	100,000,000	100,000,000	200,000,000			100,000,000
Common Stock, Number of Votes Per Share		1
Dividends, Common Stock, Total | $	$ 0
Warrants in Connection with March 2019 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares					1
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 3.125
Warrants and Rights Outstanding | $					$ 100,000
Warrants in Connection with March 2019 Offering [Member] | Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input					2.08
Warrants in Connection with March 2019 Offering [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input					0.8
Warrants in Connection with March 2019 Offering [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input					0.0234
Warrants in Connection with March 2019 Offering [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input					0
Warrants in Connection with March 2019 Offering [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input					5
Warrants in Connection With the April 2019 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares				1
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 1.375
Warrants and Rights Outstanding | $				$ 333,000
Warrants in Connection With the April 2019 Offering [Member] | Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input				0.89
Warrants in Connection With the April 2019 Offering [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input				0.83
Warrants in Connection With the April 2019 Offering [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input				0.0231
Warrants in Connection With the April 2019 Offering [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input				0
Warrants in Connection With the April 2019 Offering [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input				5
Underwriter Warrants, September 2019 [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares	1
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.375
Warrants and Rights Outstanding | $	$ 497,000
Underwriter Warrants, September 2019 [Member] | Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input	0.36
Underwriter Warrants, September 2019 [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	0.83
Underwriter Warrants, September 2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0155
Underwriter Warrants, September 2019 [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0
Underwriter Warrants, September 2019 [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	5
Second Set of Warrants Expiring September 2024 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.30
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction	0.30
Third Set of Warrants Expiring September 2024 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.375
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction	0.375
First Set of Warrants Expiring April 2024 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	1.10
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction	$ 1.10

Note 10 - Stockholders' Equit_3

Note 10 - Stockholders' Equity - Shares of Common Stock Reserved for Issuance (Details) - shares	Sep. 30, 2019	Dec. 31, 2018
Common stock reserved for issuance (in shares)	47,614,992	1,099,454
Options Issued and Outstanding [Member]
Common stock reserved for issuance (in shares)	1,862,002	865,163
Options Available for Future Grants [Member]
Common stock reserved for issuance (in shares)	351,428	223,377
Common Warrants [Member]
Common stock reserved for issuance (in shares)	45,401,562	10,914

Note 10 - Stockholders' Equit_4

Note 10 - Stockholders' Equity - Summary of Warrants Outstanding (Details)	Sep. 30, 2019$ / sharesshares
Warrants outstanding (in shares)	45,401,562
First Set of Warrants Expiring September 2024 [Member]
Warrants outstanding (in shares)	1,433,333
Exercise Price (in dollars per share) | $ / shares	$ 0.10
Second Set of Warrants Expiring September 2024 [Member]
Warrants outstanding (in shares)	30,666,667
Exercise Price (in dollars per share) | $ / shares	$ 0.30
Third Set of Warrants Expiring September 2024 [Member]
Warrants outstanding (in shares)	2,115,738
Exercise Price (in dollars per share) | $ / shares	$ 0.375
First Set of Warrants Expiring April 2024 [Member]
Warrants outstanding (in shares)	10,454,546
Exercise Price (in dollars per share) | $ / shares	$ 1.10
Second Set of Warrants Expiring April 2024 [Member]
Warrants outstanding (in shares)	636,364
Exercise Price (in dollars per share) | $ / shares	$ 1.375
Warrants Expiring March 2024 [Member]
Warrants outstanding (in shares)	84,000
Exercise Price (in dollars per share) | $ / shares	$ 3.125
Warrants Expiring December 2026 [Member]
Warrants outstanding (in shares)	10,914
Exercise Price (in dollars per share) | $ / shares	$ 22.99

Note 11 - Equity Incentive Pl_3

Note 11 - Equity Incentive Plans (Details Textual) - USD ($) $ / shares in Units, $ in Millions	Apr. 23, 2019	Nov. 30, 2016	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Jul. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			351,428		200,650
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 0.55	$ 3.59
Share-based Payment Arrangement, Expense, Tax Benefit			$ 1.1
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition			2 years 222 days
The 2007 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant						0
The 2016 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	0
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
The 2019 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,600,000

Note 11 - Equity Incentive Pl_4

Note 11 - Equity Incentive Plans - Summary of Stock Option Transactions (Details)	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Shares available for grant, beginning balance (in shares)	200,650
Number of options outstanding, beginning balance (in shares)	865,163
Weighted average exercise price, beginning balance (in dollars per share) | $ / shares	$ 8.13
Shares available for grant, authorized under 2019 Plan (in shares)	1,600,000
Shares available for grant, removed from 2016 Plan (in shares)	(223,389)
Shares available for grant, granted (in shares)	(1,413,590)
Number of options outstanding, granted (in shares)	1,413,590
Weighted average exercise price, granted (in dollars per share) | $ / shares	$ 0.76
Shares available for grant, forfeited (in shares)	165,018
Number of options outstanding, forfeited (in shares)	(212,731)
Weighted average exercise price, forfeited (in dollars per share) | $ / shares	$ 1.77
Shares available for grant, canceled (in shares)	22,739
Number of options outstanding, canceled (in shares)	(204,020)
Weighted average exercise price, canceled (in dollars per share) | $ / shares	$ 9.15
Shares available for grant, ending balance (in shares)	351,428
Number of options outstanding, ending balance (in shares)	1,862,002
Weighted average exercise price, ending balance (in dollars per share) | $ / shares	$ 3.15

Note 11 - Equity Incentive Pl_5

Note 11 - Equity Incentive Plans - Fair Value Assumptions (Details)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Minimum [Member]
Risk-free interest rate	1.89%	2.79%
Expected term (Year)	5 years 142 days	5 years 306 days
Expected volatility	83.00%	78.00%
Dividend yield
Maximum [Member]
Risk-free interest rate	2.31%	2.80%
Expected term (Year)	6 years 29 days	6 years 18 days
Expected volatility	85.00%	80.00%
Dividend yield

Note 11 - Equity Incentive Pl_6

Note 11 - Equity Incentive Plans - Total Stock-based Compensation Recognized for Options (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Stock-based compensation	$ 146	$ 183	$ 490	$ 387
Research and Development Expense [Member]
Stock-based compensation	63	92	222	195
General and Administrative Expense [Member]
Stock-based compensation	$ 83	$ 91	$ 268	$ 192

Note 12 - Net Loss Per Share _3

Note 12 - Net Loss Per Share Attributable to Common Stockholders (Details Textual) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Dilutive Securities, Effect on Basic Earnings Per Share, Total	$ 0

Note 12 - Net Loss Per Share _4

Note 12 - Net Loss Per Share Attributable to Common Stockholders - Calculation of Basic and Diluted Net (Loss) Income Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Net loss	$ (5,260)	$ (6,548)	$ (12,236)	$ (13,105)
Series B and C preferred dividend				(339)
Net loss attributable to common stockholders – diluted calculation	$ (5,260)	$ (6,548)	$ (12,236)	$ (13,444)
Shares used to compute net loss per share - basic and diluted (in shares)	16,249,032	7,141,189	12,748,665	6,038,001
Net loss per share - basic and diluted (in dollars per share)	$ (0.32)	$ (0.92)	$ (0.96)	$ (2.23)

Note 12 - Net Loss Per Share _5

Note 12 - Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	15,030,424	989,409	9,807,084	1,363,016
Share-based Payment Arrangement, Option [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	1,965,910	978,495	1,466,495	802,885
Warrant [Member] | Convertible Preferred Stock [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)				1,191
Warrant [Member] | Common Stock [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	13,064,514	10,914	8,340,589	9,195
Series B and C Convertible Preferred Stock, Including Cumulative Dividends [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)				285,797
Series A Convertible Preferred Stock [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)				16,391
Convertible Debt Securities [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)				247,557

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) $ in Millions	3 Months Ended
	Dec. 31, 2019USD ($)
Subsequent Event [Member]
Amortization of Debt Issuance Costs	$ 0.1